Drug intelligence / Profile preview

64Cu-Tamrada

Development stage: Preclinical
Lead developer: Ironfist Therapeutics
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

**64Cu-Tamrada** is the copper-64 imaging member of Ironfist Therapeutics' Tamrada theragnostic radiopharmaceutical program. It is a hydroxyl-dendrimer nanomedicine designed to selectively accumulate in tumor-associated macrophages within the tumor microenvironment without use of a conventional targeting ligand. The copper-64 label supports PET-based tumor localization and dosimetry to guide paired treatment with 177Lu-Tamrada. The program is preclinical and is being evaluated across solid tumors, including preclinical triple-negative breast cancer models.

Other names: 64Cu-Tamrada[64Cu]Cu-Tamrada

Targets

TAM (TAM receptor tyrosine kinases)

Beyond the preview

Go deeper on 64Cu-Tamrada.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 64Cu-Tamrada.

Explore the full profile